S63845 treatment (25 mg/kg) led to a complete tumor regression at day 100 post-treatment in xenograft models of MM and a 70% cure rate in immune-competent Eμ-MYC mouse lymphomas, respectively [109]. This evidence concerns the gene MYC and neoplasm.